(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
(-)-Epigallocatechin Gallate Chemical Structure
CAS No. : 989-51-5
This product is a controlled substance and not for sale in your territory.
Based on 34 publication(s) in Google Scholar
Other Forms of (-)-Epigallocatechin Gallate:
(-)-Epigallocatechin Gallate (Standard)
In-stock
(-)-Epigallocatechin
In-stock
(-)-Gallocatechin gallate
In-stock
(+/-)-Epigallocatechin Gallate-13C3
Obtenir un devis
(-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in:
Oncol Lett. 2017 Nov;14(5):6314-6320.
[Abstract]
Effects of EGCG on the levels of SHP 1 and p p38α protein expres¬sion in NB4 cells.
Powered by Bioz
See more details on Bioz
Description
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].
IC50 & Target[1]
EGFR
HER2
HER3
In Vitro
(-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner[1].
(-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression[1].
(-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration[1].
(-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)[2].
(-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase[3].
(-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
(-)-Epigallocatechin Gallate Related Antibodies
Cell Proliferation Assay[1]
Cell Line:
FB-2 and WRO cells (serum-starved for 48h)
Concentration:
10, 40, 60 μM.
Incubation Time:
4 days
Result:
Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).
Western Blot Analysis[1]
Cell Line:
FB-2 cells
Concentration:
10, 40, 60 μM.
Incubation Time:
24 h
Result:
Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2.
Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin.
Cell Migration Assay [1]
Cell Line:
FB-2 and WRO cells (serum-starved for 48h)
Concentration:
10, 40, 60 μM.
Incubation Time:
12 h
Result:
Reduced migration activity in FB-2 and WRO cells.
RT-PCR[4]
Cell Line:
Mouse primary osteoblasts (1 ng/ml LPS-treated)
Concentration:
30 μM
Incubation Time:
3, 6, 12, 24 h
Result:
Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.
In Vivo
(-)-Epigallocatechin Gallate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth[3].
(-)-Epigallocatechin Gallate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Orthotopic transplant BALB/c nude mice model[3]
Dosage:
5, 10, and 20 mg/kg, once daily for 14 days.
Administration:
Intragastrical administration.
Result:
Inhibited tumors growth with no liver or lung metastases.
Animal Model:
Model of experimental periodontitis, LPS (25 μg/mouse)[4]
Dosage:
0.5 mg/mouse, a single dose.
Administration:
Injected into the mouse lower gingiva
Result:
Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.
Room temperature in continental US; may vary elsewhere.
Stockage
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
Solvant et solubilité
In Vitro:
DMSO : ≥ 30 mg/mL (65.45 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 20 mg/mL (43.63 mM; Need ultrasonic)
*"≥" means soluble, but saturation unknown.
Preparing Stock Solutions
ConcentrationSolventMass
1 mg
5 mg
10 mg
1 mM
2.1816 mL
10.9082 mL
21.8164 mL
5 mM
0.4363 mL
2.1816 mL
4.3633 mL
10 mM
0.2182 mL
1.0908 mL
2.1816 mL
View the Complete Stock Solution Preparation Table
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
*
Note: If you choose water as the stock solution, please dilute it to the working solution,
then filter and sterilize it with a 0.22 μm filter before use.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (20.8 mg/mL) to 900 μLCorn oil, and mix evenly.
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution.
If precipitation or phase separation occurs during preparation,
heat and/or sonication can be used to aid dissolution.
Protocol 1
Add each solvent one by one: PBS
Solubility: 9.09 mg/mL (19.83 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage
mg/kg
Animal weight (per animal)
g
Dosing volume (per animal)
μL
Number of animals
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration:
mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
[1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1.
[Content Brief]
[2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4.
[Content Brief]
[3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53.
[Content Brief]
[4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7.
[Content Brief]
[1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1.
[2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4.
[3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53.
[4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7.
Complete Stock Solution Preparation Table
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent
ConcentrationSolventMass
1 mg
5 mg
10 mg
25 mg
H2O / DMSO
1 mM
2.1816 mL
10.9082 mL
21.8164 mL
54.5411 mL
5 mM
0.4363 mL
2.1816 mL
4.3633 mL
10.9082 mL
10 mM
0.2182 mL
1.0908 mL
2.1816 mL
5.4541 mL
15 mM
0.1454 mL
0.7272 mL
1.4544 mL
3.6361 mL
20 mM
0.1091 mL
0.5454 mL
1.0908 mL
2.7271 mL
25 mM
0.0873 mL
0.4363 mL
0.8727 mL
2.1816 mL
30 mM
0.0727 mL
0.3636 mL
0.7272 mL
1.8180 mL
40 mM
0.0545 mL
0.2727 mL
0.5454 mL
1.3635 mL
DMSO
50 mM
0.0436 mL
0.2182 mL
0.4363 mL
1.0908 mL
60 mM
0.0364 mL
0.1818 mL
0.3636 mL
0.9090 mL
*
Note: If you choose water as the stock solution, please dilute it to the working solution,
then filter and sterilize it with a 0.22 μm filter before use.
(-)-Epigallocatechin Gallate Related Classifications
Inflammation/ImmunologyCancer
Cancer Targeted TherapyCancer ImmunotherapyCancer Metabolism and Metastasis
Metabolic Enzyme/ProteaseApoptosis
Endogenous MetaboliteApoptosis
Help & FAQs
Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Telefone : +1 850 650 7790